Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study - PubMed
4 hours ago
- #Mavacamten
- #Hypertrophic Cardiomyopathy
- #Patient-Reported Outcomes
- Mavacamten was evaluated for health status improvements in Chinese patients with obstructive hypertrophic cardiomyopathy over up to 78 weeks.
- In the double-blind period, mavacamten improved KCCQ-23 scores (e.g., CSS, OSS), while placebo worsened scores.
- Sustained improvements in health status were observed during long-term extension with mavacamten treatment.
- Patients switching from placebo to mavacamten also showed significant score improvements after the switch.
- The study supports long-term mavacamten use for enhancing quality of life in symptomatic obstructive HCM patients.